Abstract：
Human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2) is a newly emerging immune checkpoint that belongs to B7 family. HHLA2 has a co-stimulatory receptor transmembrane and immunoglobulin domain containing 2 (TMIGD2) and a newly discovered co-inhibitory receptor killer cell Ig-like receptor, three Ig domains, and long cytoplasmic tail (KIR3DL3), which endows it with both immunostimulant and immunosuppression functions in cancer development. In this review, we summarize the HHLA2 expression profile in human cancers, its association with cancer prognosis and clinical features, and its dual roles in regulating cancer immune response through up-to-date literatures. Furthermore, we highlight that precision cancer immunotherapy through manipulating HHLA2-KIR3DL3/TMIGD2 interaction is a promising antitumour strategy.
摘要：
人内源性逆转录病毒-H长末端重复序列关联2（HHLA2）是一种新兴的免疫检查点，属于B7家族。HHLA2具有包含共刺激受体跨膜和免疫球蛋白结构域2（TMIGD2）和新发现的共抑制受体杀伤细胞Ig样受体，三个Ig域,和长细胞质尾（KIR3DL3），这赋予了它在癌症发展中的免疫刺激和免疫抑制功能。在这次审查中,我们总结了HHLA2在人类癌症中的表达谱，其与癌症预后和临床特征的关系，及其在调节癌症免疫应答中的双重作用。此外，我们强调,通过操纵HHLA2-KIR3DL3/TMIGD2相互作用进行精准癌症免疫治疗是一种有前景的抗肿瘤策略.
